Daridorexant,
does it really help with Improved sleep onset, sleep maintenance, and daytime functioning in adult insomnia?
research showsDaridorexant is rated B for improving sleep onset, sleep maintenance, and some daytime function in adult insomnia, but 76 points was too high. The 50-mg dose consistently improved wake after sleep onset, latency to persistent sleep, total sleep time, and IDSIQ, but it appeared in only one of the two phase 3 trials. The 25-mg dose was not fully consistent for latency or IDSIQ, and 10 mg failed the key objective endpoints. A 40-week extension offered exploratory persistence signals, while every source trial and extension was concentrated in the Idorsia program. Dose dependence and lack of independent source-trial replication give B with 72 points.
ads claimClaims of completely restored natural sleep, zero next-day effects, or a dependence-free lifetime sleeping pill exceed the evidence. Trials showed average improvements in sleep and daytime function, not guaranteed restorative sleep, unimpaired driving, or absence of long-term misuse risk for every patient.
Useful facts when choosing a product
- Daridorexant blocks both orexin OX1 and OX2 receptors and is a prescription hypnotic generally taken immediately before bedtime with adequate time available for sleep.
- CYP3A4 inhibitors or inducers, alcohol, opioids, and other central nervous system depressants can alter exposure or sedation and require medication review.
- Headache and somnolence can occur, with rare sleep paralysis, hypnagogic or hypnopompic hallucinations, and cataplexy-like symptoms.
- Next-day residual effects and physical dependence appeared lower than with benzodiazepine-type hypnotics, but this does not mean driving impairment and misuse risk are absent.
What the research actually shows
Mignot and colleagues enrolled adults with insomnia disorder at 156 sites in 17 countries. Study 1 assigned 930 participants to 50 mg, 25 mg, or placebo, and study 2 assigned 924 to 25 mg, 10 mg, or placebo for three months. Polysomnography measured wake after sleep onset and latency to persistent sleep, while total sleep time and IDSIQ were patient reported; the most complete nighttime and daytime benefit occurred with 50 mg. In a 40-week double-blind extension, self-reported total sleep time and IDSIQ total-score benefits with 50 mg persisted at several time points, but efficacy was exploratory and the placebo sample was small. An independent meta-analysis reanalyzed short-term results but did not add independent source trials.
Why this is classified as B (72)
Across 1,854 participants, efficacy signals were present, but the most consistent improvements in latency, wake after sleep onset, total sleep time, and IDSIQ came from 50 mg in only one phase 3 trial. The 25-mg latency and IDSIQ results were not fully consistent, 10 mg failed key objective endpoints, all source trials were concentrated in the Idorsia program, and long-term efficacy was exploratory. This gives B with 72 points. Somnolence, sleep paralysis, and driving impairment remain separate safety concerns.
Counterpoint. Daridorexant does not replace cognitive behavioral therapy for insomnia or assessment of sleep, psychiatric, and medical causes. When medicine is needed, next-day activities, concomitant sedatives, respiratory disease, and fall risk should guide dose and duration.
Rejudgment record. New verdict — Assigned B because 50 mg consistently improved latency, wake after sleep onset, total sleep time, and IDSIQ in one phase 3 trial, whereas 25 mg was not fully consistent for latency or IDSIQ, 10 mg failed key objective endpoints, and all source trials were concentrated in the Idorsia program
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved sleep onset in adults with insomnia disorder | B | Latency was positive with 50 mg, but that dose appeared in only one phase 3 trial; 25 mg was not fully consistent across trials, and 10 mg failed key objective endpoints. |
| Improved sleep maintenance in adults with insomnia disorder | B | Wake after sleep onset and self-reported total sleep time improved; long-term extension evidence was exploratory. |
| Improved daytime functioning in adults with insomnia disorder | B | The effect was dose dependent, and the most consistent daytime-function benefit appeared only on IDSIQ with 50 mg in one phase 3 trial. Next-day residual effects and physical-dependence concerns are not absent. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Mignot E et al. 2022 phase 3 program | Two multicenter randomized double-blind placebo-controlled phase 3 trials | 1,854 | Sponsored by Idorsia Pharmaceuticals with company-employed coauthors | Polysomnographic wake after sleep onset and latency to persistent sleep, self-reported total sleep time, and IDSIQ daytime sleepiness | The 50-mg dose, included in only one trial, consistently improved wake time, latency, total sleep time, and IDSIQ; 25 mg was not fully consistent for latency or IDSIQ, and 10 mg failed key objective endpoints. | Pivotal large direct nighttime and daytime evidence with dose dependence and manufacturer concentration |
| Jiang F et al. 2023 meta-analysis | Systematic review and meta-analysis of randomized daridorexant trials | 3 | Chinese academic investigators; no commercial sponsorship reported | Wake after sleep onset, latency to persistent sleep, self-reported total sleep time, IDSIQ, and adverse events | The 50-mg dose significantly improved wake after sleep onset, latency, total sleep time, and IDSIQ versus placebo. | Independent synthesis but based on overlapping source trials |
| Kunz D et al. 2023 extension | Forty-week double-blind extension in phase 3 completers | 804 | Sponsored by Idorsia Pharmaceuticals with company-employed coauthors | Long-term safety with exploratory total sleep time and IDSIQ | No new safety signal emerged, and self-reported sleep and daytime-function gains with 50 mg persisted at several time points. | Supportive long-term evidence with exploratory efficacy |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Daridorexant x improved sleep and daytime functioning in adult insomnia — Evidence Grade B·72. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/sleep/daridorexant-adult-insomnia-sleep-and-daytime-function/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.